Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Comparison of bronchodilator effect of salbutamol delivered via MDI + spacer and DPI in children with asthma Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012
Nebulized salbutamol through the ultrasonic nebulizer during sputum induction improves the bronchoprotection in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Safety and efficacy of formoterol delivered via a novel DPI device in children with asthma Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management Year: 2010
Efficacy of combined budesonide/formoterol delivered via turbuhaler on lung function and asthma control in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 496s Year: 2003
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI Source: Eur Respir J 2003; 21: 816-820 Year: 2003
Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001